GlassScriptPhysician profile
Matthew E Funderburk
NPI 1497765341
$1,805.14
in general payments reported to CMS, 2019-2025
21 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.18 · 2021: $237 · 2022: $283 · 2023: $431 · 2024: $354 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,273.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $341.70 | 2022-2025 | |
| Edwards Lifesciences Corporation | $309.60 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astellas Pharma US INC | $211.44 | 2021 | |
| Pfizer INC. | $148.59 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.27 | 2023-2025 | Jardiance |
| Irhythm Technologies, INC. | $115.15 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Cvrx, INC. | $96.67 | 2023-2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $59.39 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $54.69 | 2023-2025 | Camzyos, Eliquis |
| Amgen INC. | $48.33 | 2022 | |
| Boston Scientific Corporation | $38.50 | 2025 | Watchman Flx, Watchman |
| Inspire Medical Systems, INC. | $35.14 | 2024-2025 | Inspire |
| Novo Nordisk INC | $31.00 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Impulse Dynamics (USA) INC. | $28.48 | 2024 | Optimizer |
| Merck Sharp & Dohme LLC | $28.17 | 2022-2023 | Verquvo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $25.77 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $25.02 | 2019-2023 | Farxiga |
| Alnylam Pharmaceuticals INC. | $23.76 | 2024 | Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $22.29 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $15.88 | 2024 | |
| Sanofi-Aventis U.S. LLC | $15.30 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Funderburk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.